Mindray Medical International (MR) Tops Q2 EPS by 2c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Goldman Sachs Comments on Mindray Medical (MR) Following Q2 Results
August 12, 2014 3:10 PM EDTGoldman Sachs maintained a Neutral rating on Mindray Medical (NYSE: MR) with a price target of $30.10 (from $30.80). Comments follow Q2 results.
Analyst Wei Du said, "China revenue growth continued to decelerate 3.4% yoy to US$152.5 mn, as hospitals were reluctant towards capex spending.... More
